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The p21 membrane protein of vaccinia virus (VV), encoded by the A17L gene, has been reported to localize on the inner
of the two membranes of the intracellular mature virus (IMV). It has also been shown that p21 acts as a membrane anchor
for the externally located fusion protein p14 (A27L gene). Since p14 is located on the surface of IMVs, it is hard to envision
that p21 should be located only on the inner membrane. Our results from (i) immunoelectron microscopy, (ii) biotinylation, and
(iii) protease treatment of purified IMVs showed that the N-terminus of p21 is exposed on the surface of virus particles, while
the C-terminus is embedded in the membrane. Mono-specific antibodies to the N-terminus of p21 neutralize infection of VV
while antibodies to the C-terminal domain do not. We suggest that p21 molecules are located both in the inner and in the outer
membrane of IMV. © 2001 Academic Press
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Vaccinia virus (VV) is one of the largest and most
complex animal viruses with its double-stranded DNA
genome encoding about 200 genes. Approximately half
of these are structural proteins, which are incorporated
into the viral particles, while the rest are required in the
complicated replication machinery applied by the virus
or modulate, e.g., the immune response to the virus. The
virus forms viral factories in the cytoplasm of the infected
cell, where replication and assembly occur (reviewed in
Moss, 1996). Two main infectious forms of virus are
produced during the course of infection: the intracellular
mature virus (IMV) and the extracellular enveloped virus
(EEV) (Appleyard et al., 1971). The IMV consists of a
nucleoprotein complex or core surrounded by an enve-
lope. The IMV envelope is thought to derive from mem-
branes of the intermediate compartment (ERGIC) be-
tween the endoplasmic reticulum and the Golgi complex
and thus consist of a double membrane (Sodeik et al.,
1993). An alternative hypothesis for the IMV envelope is
that it is a single membrane, which is synthesized de
novo (Dales and Mosbach, 1968; Hollinshead et al.,
1999). These membranes are modified by the insertion of
viral proteins to give rise to the rigid, crescent-shaped
membranes that assemble around the cytoplasmic viral
factory (reviewed in Moss, 1996). During a process that is
poorly understood, the membranes engulf electron-
dense material from the factory to form spherical imma-1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 34 91 585 4506. E-mail: mesteban@cnb.uam.es.
143ture virions (IVs) (Dales and Pogo, 1981; Dales and Simi-
novitch, 1961; Ichihashi et al., 1971), which are enveloped
by a double membrane (Risco et al., unpublished data).
The spherical IVs then mature into brick-shaped IMVs,
through a mostly unknown mechanism that involves pro-
teolytic cleavage of VV proteins (Katz and Moss, 1970;
Moss and Rosenblum, 1973; Vanslyke et al., 1993).
The product of the A17L gene, p21, is essential for
virus morphogenesis and constitutes one of the major
components of the IMV membrane, together with p15
(A14L) and p8 (A13L) (Salmons et al., 1997). While p21
appears to be responsible for organizing the ERGIC-
derived membranes into crescents, p15 seems to be
responsible for the assembly of the crescent in close
contact with the content of the factory (Rodrı´guez et al.,
1997, 1998; Traktman et al., 2000).
p21 is synthesized in the endoplasmic reticulum as a
23-kDa precursor of 203 amino acids (aa). The precursor
is proteolytically cleaved at aa 17 (Rodrı´guez et al., 1993;
Whitehead and Hruby, 1994) and has also been sug-
gested to be processed in its C-terminus (Betakova et al.,
1999b). The protein is phosphorylated (Betakova et al.,
1999b; Derrien et al., 1999) and contains potential sites
for myristylation. p21 has two long stretches of hydro-
phobic aa residues, and it has been demonstrated that
both ends of the protein are oriented toward the cyto-
plasm (Krijnse-Locker et al., 1996; Betakova et al., 1999a).
Two models for the topology of p21 have been sug-
gested. One model predicts that p21 spans the mem-
brane four times (Krijnse-Locker et al., 1996; Rodrı´guez et
al., 1993), whereas the other model suggests a two-
transmembrane conformation (Betakova et al., 1999a).
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144 WALLENGREN ET AL.Recent results support the latter model (Betakova and
Moss, 2000).
It has previously been shown that p21 forms a complex
with the 14-kDa protein (p14) encoded by the A27L gene
(Rodrı´guez et al., 1993) and with p15 (A14L) (Betakova et
l., 1999b; Rodrı´guez et al., 1997). While p15 behaves as
n integral membrane protein, p14 is a peripheral protein
ocated on the surface of IMV and has been postulated to
ediate fusion (Chung et al., 1998; Doms et al., 1990;
Gong et al., 1990; Lai et al., 1990; Rodrı´guez et al., 1987;
Sodeik et al., 1995; Va´zquez and Esteban, 1999). p14 has
a structural organization much like the influenza hemag-
glutinin and gp41 of HIV, except that no transmembrane
anchor can be predicted from its sequence (Va´zquez et
al., 1998). Instead, it has a domain that binds to p21,
which thus is believed to serve as membrane anchor for
p14 (Rodrı´guez et al., 1993). Through protein binding
studies in vitro and in vivo of mutant forms of p14, the p21
binding domain has been predicted to involve a Leu
zipper in the third a-helix in the C-terminus of the 14-kDa
protein (Va´zquez et al., 1998).
The 14-kDa protein has been localized to the exterior
of IMV particles using immunoelectron microscopy (im-
muno-EM) (Sodeik et al., 1995), while p21 has been
reported to localize to the innermost of the two mem-
branes of IV (Krijnse-Locker et al., 1996; Wolfe et al.,
1996). This conclusion is based on results from immu-
nolabeled cryosections of infected cells. EM analysis of
IMV has not demonstrated any specific localization for
p21 on the inner or the outer membrane (Betakova et al.,
1999b). However, the fact that p21 interacts directly with
the externally located p14 suggests that p21 localization
should be reexamined. Therefore we have studied the
localization of p21 in IMV by different biochemical ap-
proaches and by immunoelectron microscopy using an-
tibodies that recognize different domains of the protein.
RESULTS
Characterization of a panel of anti-A17L antibodies
It has previously been shown that the A17L gene
product is synthesized as a 23-kDa precursor that is
proteolytically processed within cells at both the N-
(Rodrı´guez et al., 1993; Whitehead and Hruby, 1994) and
the C-termini (Betakova et al., 1999b). A set of polyclonal
antibodies was generated to peptides corresponding to
different regions of the A17L gene product. Both purified
VV and lysate of VV-infected BSC-40 cells (collected at
24 h postinfection (hpi)) were analyzed by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS–
PAGE) and Western blot to determine the specificity and
pattern of recognition of these antibodies. As shown in
Fig. 1, all antibodies (aA17L N9, aA17L C9, and aA17L C)
ere able to identify the 23-kDa precursor in infected
ells (lanes 1, 3, and 5). In virus particles, however, the
3-kDa precursor was not detected by any of the anti-odies (lanes 2, 4, and 6). Antibodies aA17L N9 and
aA17L C9 also recognized a protein of 21 kDa believed to
be the mature product of A17L (Betakova et al., 1999b;
Rodrı´guez et al., 1993; Whitehead and Hruby, 1994) both
in extracts of infected cells (lanes 1 and 3) and in virus
particles (lanes 2 and 4). However, the most C-terminal
antibody, aA17L C, was unable to detect the 21-kDa
roduct, neither in cell lysates nor in virus particles
lanes 5 and 6).
To more thoroughly characterize the products recog-
ized by the aA17L antibodies, a pulse–chase and im-
munoprecipitation analysis was set up. VV-infected cells
were metabolically labeled with [35S]methionine for 5 min
nd then chased with an excess of cold methionine for
5, 30, 60, and 120 min before collection in lysis buffer.
roteins were immunoprecipitated with aA17L N9, aA17L
C9, or aA17L C and separated by SDS–PAGE. The pro-
teins were transferred to a nitrocellulose filter, which
was used for both autoradiography and visualization by
ECL after antibody recognition. All three antibodies de-
tected the 23-kDa precursor, which could be visualized
as a doublet, and showed that this protein decreases in
amount with time (Fig. 2). After immunoprecipitation with
aA17L N9 and aA17L C9 antibodies, the 21-kDa product
FIG. 1. Processing of VV A17L gene product. Western blot analysis of
extracts from BSC-40 cells infected with VV (10 PFU/cell) for 24 h (C)
and of purified virions (V). The proteins were separated by SDS–PAGE
(12% polyacrylamide), transferred to nitrocellulose paper, and reacted
with different antibodies to p21: aA17L N9, aA17L C9, or aA17L C.
Antibody reactivity was detected using ECL.could be detected at the 30-min chase point and in-
creases in amount with time. At 120 min postsynthesis,
a145A17L GENE PRODUCT OF VACCINIA VIRUSmost 23-kDa precursor has been processed. Again,
aA17L C is not able to immunoprecipitate p21. We also
observed protein bands, which migrated between the
precursor and the mature p21, that may represent cleav-
age intermediates.
A protein of approximately 15 kDa was found to co-
precipitate with p21, using all of the above antibodies. It
appears in samples from the 30-min chase point and
onward. The protein was identified as p15 (A14L gene
product) by incubating the filter with the corresponding
antibody (not shown). This is in agreement with previous
results showing that this interaction occurs even before
C-terminal truncation of the A17L precursor (Betakova et
al., 1999b).
Localization of p21 on the surface of IMVs by
immunoelectron microscopy
Purified IMVs from WR-infected cells were processed
for immunogold labeling. Particles were then subjected
to negative staining and studied by electron microscopy.
Electron micrographs of purified IMVs show extensive
surface labeling when using antibodies raised to the
entire p21 protein (Fig. 3A). Similarly, strong surface la-
beling was observed with antibodies directed to the
N-terminus of p21 (Fig. 3B). As controls, we included
antibodies to the peripheral p14 protein, as well as an-
tibodies directed to the p39 core protein. The antibody to
the externally located p14 gave rise to abundant surface
labeling of IMV (Fig. 3C), while no surface labeling was
FIG. 2. Time course of proteolytic processing of the 23-kDa precur-
sor. BSC-40 cells infected (5 PFU/cell) with VV were metabolically
labeled with [35S]methionine for 5 min at 6 hpi. Cells were then chased
with a 100-fold excess of unlabeled methionine for 15, 30, 60, and 120
min and lysed, as indicated at the top of the figure. Proteins were
immunoprecipitated with antibodies aA17L N9, aA17L C9, or aA17L C
nd analyzed by 12% SDS–PAGE followed by autoradiography.observed when using an antibody directed to the p39
core protein (Fig. 3D). These results showed that p21 dwas present on the surface of IMVs. The labeling with
anti-p21 antibodies directed either to the entire protein or
to the N-terminal region was as extensive as that ob-
served with anti-p14 antibodies (10–20 gold particles per
virion), which points to an abundant surface distribution
of both p21 and p14. An antibody recognizing the C-
terminal region of the A17L protein, A17L C9, was not
able to label the surface of the IMV particles (Fig. 3) but
it did label thin sections of IMV particles, indicating that
only the N-terminal domain of p21 is exposed on the IMV
surface. The results from IMV immunolabeling with dif-
ferent antibodies, and from other biochemical assays on
intact IMVs to be described in the following sections, are
summarized in Table 1.
Biotinylation of p21 on the surface of IMV
To confirm the localization of p21, purified IMVs were
incubated with NHS-SS-Biotin sulfosuccinimidyl-2-(bio-
tinamido)ethyl-1,3-dithioproprionate) in order to label sur-
face proteins. The biotinylation reaction was stopped by
adding NH4Cl and then particles were extensively lysed
under nonreducing conditions to avoid breaking the di-
sulfide bridge of the biotin component. The biotinylated
proteins were precipitated with streptavidin–agarose
and analyzed by SDS–PAGE in parallel with the corre-
sponding nonbiotinylated sample and identified after
Western blot and ECL (Fig. 4). Proteins were quantified
using NIH Image 1.59. The results are presented in Table
1 as the amount of biotinylated protein as a percentage
of the total sample (biotinylated and nonbiotinylated).
The results show that p21 was precipitated using
streptavidin–agarose, thus confirming the presence of
p21 on the surface of IMVs. However, biotinylated p21
accounted for only approximately 50% of the total amount
of p21, indicating that there might exist an internal pool of
p21, which was not accessible for biotinylation. As a
control, we quantified the amount of biotinylated surface
protein p14 as well as the internally localized core pro-
tein p62 (A10L). As shown in Table 1, 97% of p14 was
biotinylated, which would be expected considering its
localization on the surface of the particle, while p62 was
26% biotinylated.
The N-terminal part of p21 was sensitive to protease
digestion
To study the topology and localization of p21 in IMV,
we treated purified IMV with increasing concentrations
of trypsin (0.2, 2, 20, and 200 mg/ml). The protease-
treated particles were then analyzed by SDS–PAGE fol-
lowed by Western blot. p21 was identified with antibod-
ies aA17L N9 or aA17L C9 and visualized by ECL. The
results show that the N-terminal part of p21 was sensi-
tive to protease cleavage (Fig. 5a). With increasing con-
centrations of trypsin, the aA17L N9 antibody ceased to
etect p21 and, after treatment with 200 mg/ml, the N-
esult in
antibo
146 WALLENGREN ET AL.terminal part of p21 was completely digested. On the
other hand, the C-terminal part of p21 turned out to be
protease resistant since there was no decrease in the
amount of protein even at high concentrations of trypsin.
FIG. 3. Electron micrographs showing immunogold surface labelin
antibodies directed to the entire p21. (B) The N-terminal region of p21 pr
of purified virions with the antibodies to the N-terminus of p21. (C) Th
peripheral p14 protein. (D) The VV p39 core protein is not detected whe
(A17L C9) antibody gives no signal on the surface of IMV particles. The r
since thin sections of IMV particles are clearly labeled with the sameHowever, digestion of the N-terminal part was reflected
in the protein detected by the C-terminal antibody thatdecreased in size concomitantly with the disappearance
of aA17L N9-signal with an increasing amount of pro-
tease. These results indicate that the N-terminus of the
p21 protein is exposed on the surface of IMV where it is
rified virions. (A) The surface of IMV is extensively labeled with the
exposed on the surface of IMVs, as revealed by immunogold labeling
ce of IMVs is also extensively labeled with antibodies directed to the
ce labeling purified virions. (E) Immunogold labeling with the anti-p21
dicates that this part of the protein is not exposed on the viral surface,
dy (F).g of pu
otein is
e surfa
n surfaaccessible for protease digestion. The C-terminus, on
the other hand, was protected from proteolysis. To certify
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147A17L GENE PRODUCT OF VACCINIA VIRUSthat the particles were intact, IMVs treated with 200
mg/ml trypsin were reacted with antibodies to two pro-
teins, which previously have been found to localize fac-
ing the inner side of the virion envelope, the proteins p65
(D13L) (Sodeik et al., 1994) and p15 (A14L) (Salmons et
al., 1997; Traktman et al., 2000). As shown in Fig. 5b, p15
was resistant to protease treatment. Similarly, p65 re-
mained intact after protease treatment (not shown). On
the other hand, when protease-treated virions were an-
alyzed with antibodies to IMV surface proteins, we ob-
served that p14 was completely digested (Fig. 5c) while
p8 (A13L), described to be present in both the inner and
the outer membranes of IMV (Salmons et al., 1997), was
partially sensitive and p32 (D8L) shifted from 32 kDa to
approximately 30 kDa following trypsin treatment (not
shown), as has been demonstrated previously (Maa et
al., 1990; Niles and Seto, 1988). However, the degree of
protease resistance varied between experiments, sug-
gesting that there did exist some leakiness of the mem-
T
Summary of Res
IMV proteins detected by different antibodies Protease sensiti
urface protein p14 (A27L) S
embrane protein p21 N9 (A17L) S
p21C9 (A17L) R
p8 (A13L) S/R
p15 (A14L) R
Membrane associated p32 (D8L) S
p65 (D13L) R
Internal protein p62 (A10L) ND
Note. Characteristics of VV proteins from protease-treated, biotinylat
to trypsin; R, resistant; ND, not determined. Biotinylation; figures repre
labeling; gold immunolabeled purified IMV with corresponding antibod
FIG. 4. Biotin labeling of purified IMVs. Biotinylated proteins were
precipitated with streptavidin–agarose (P), analyzed by SDS–PAGE in
parallel with the corresponding supernatant (S), and identified after
Western blot and ECL using the indicated antibodies.branes. The characteristic results are summarized in
Table 1.
Neutralization of VV infection
To determine the biological effect of the p21 antibod-
ies, we examined their neutralizing effect on VV infection.
m Purified IMVs
Biotinylation % EM surface labelling Neutralization of infection
97 6 5 111 1
34 6 16 111 1
53 6 13 2 2
ND 11 ND
ND 1 2
62 6 8 11 ND
ND 2 ND
26 6 6 2 ND
urface-labeled IMVs. Protease treatment of purified IMVs; S, sensitive
e percentage of the total amount of protein biotinylated. EM surface
mber of plus signs indicates abundance of surface immunolabeling.
FIG. 5. Trypsin treatment of purified IMV. Purified VV were treated
with trypsin at various concentrations (0.2, 2, 20, and 200 mg/ml) (lanes
–5 and 6–9) for 30 min at 37°C. Lane 1 is not trypsin treated. Digestion
as stopped by treatment with aprotinin and PMSF and proteins were
eparated by 12% SDS–PAGE, transferred to nitrocellulose membrane,
nd reacted with (a) antibodies aA17L N9 (lanes 1–5) and aA17L C9ABLE 1
ults fro
vity
ed, or s(lanes 6–10). Proteins from untreated and trypsin-treated IMV particles
were probed with anti-p15 antibodies (b) or anti-p14 antibodies (c).
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148 WALLENGREN ET AL.VV was incubated with different dilutions of antibody
(1:100 and 1:500) prior to virus adsorption to monolayers
of BSC-40 cells. The infected cultures were incubated in
solid medium for 48 h and viral plaques were stained
with crystal violet and counted. The results presented in
Fig. 6 clearly show that the A17L N9 antibody had a
neutralizing effect on virus infection. The number of
plaques was reduced by approximately 80% after prein-
cubation of WR VV with the antibody at the two dilutions
tested (1:100 and 1:500) compared to untreated virus
(Fig. 6). Moreover, the neutralizing effect of the A17L
N-terminal antibody was similar to that of antibody di-
rected to the surface envelope protein p14. In addition,
the polyclonal antibody raised against the entire p21
neutralized VV infection as efficiently as did ap14 (A27L).
n the contrary, neither aA17L C, directed to the extreme
C-terminal part of the 23-kDa precursor, nor aA17L C9,
directed to the processed C-terminus of p21, showed any
significant neutralizing activity (approximately 20%). As
negative controls we used an antibody recognizing the
VV core protein p62 and an antibody to an unrelated
protein, the HIV gp120.
DISCUSSION
In the current work, we have examined the localization
of the VV A17L gene product in the infectious IMV form.
This protein is synthesized in the rough ER as a 23-kDa
precursor, which is processed at both ends to generate
the mature p21. Based on aa sequence, N-terminal pro-
cessing has been described to occur between aa 16 and
FIG. 6. Neutralization of VV infection. VV infection is neutralized by
antibody directed to the surface protein p14. Antibodies to the N-
terminus of p21 (A17L N9) or to the entire p21 (p21E) neutralizes VV
infection at least as efficiently as p14 antibody, indicating the presence
of p21 on the surface of virions. Antibodies directed to the C-terminus
of the 23-kDa precursor (A17L C) or mature p21 (A17L C9) have no
neutralizing effect. Antibodies to the VV internal core protein p62 or the
unrelated HIV gp120 have no neutralizing effect on VV infection.17 (Rodrı´guez et al., 1993) at an Ala-Gly-Ala motif (White-
head and Hruby, 1994). Proteolytic processing at the
q
TC-terminus of p21 has been described and probably
occurs at aa 185, at an Ala-Gly-Asn motif as previously
suggested (Betakova et al., 1999b).
The antibodies used in this study were characterized
in relation to the processed products of the 23-kDa
precursor. Our results confirm the above-indicated pro-
cessing, which we showed occurs approximately 30 min
after synthesis. Several intermediate bands between the
23-kDa and the 21-kDa products were detected by the
different p21 antibodies. These bands probably repre-
sent intermediate cleavage products. Only the mature
form of p21 could be detected in IMVs.
p21 has previously been shown to interact with p15
(A14L) (Rodrı´guez et al., 1997), one of the other abundant
membrane proteins of IMV. In pulse–chase analysis we
found that coprecipitation of p15 can be first observed 30
min after the chase, indicating that this interaction oc-
curs early after A17L protein synthesis. Coprecipitation
was observed with all three antibodies, indicating that
cleavage of the 23-kDa precursor is not required for this
interaction to occur. This is in agreement with the results
obtained by Bekatova et al. (1999b) showing that anti-
bodies against p15 were able to coprecipitate both trun-
cated and nontruncated forms of the A17L protein.
In contrast to the previously reported results stating
that p21 is located mainly on the inner membrane of IV
particles (Krijnse-Locker et al., 1996; Wolfe et al., 1996),
our results from immunoelectron microscopy of purified
IMV clearly show that p21 is located on the surface of
IMV particles and hence in the outer membrane. Anti-
bodies to p21 give rise to surface labeling, which is as
extensive as immunolabeling of the external protein p14,
indicating that p21 is present on the surface to the same
extent as p14. This is in accordance with the idea that
p21 acts as the membrane anchor for p14.
The results from immuno-EM of surface labeled IMVs,
summarized in Table 1, are in accordance with the ex-
posure of different VV proteins. p32 and p8 are mem-
brane proteins that are readily exposed on the surface of
IMVs, although they are not labeled with antibodies as
strongly as p14 or p21. p15 appears to be a less exposed
membrane protein, since it gives rise to poor, but con-
sistent labeling (Rodrı´guez et al., 1997). On the other
hand, p65, being an internal membrane-associated pro-
tein (Sodeik et al., 1994), is not exposed on the surface
nd thus does not give rise to any surface labeling
etected by EM, and the same is true for the core protein
39.
Following treatment of purified IMV with biotin, we
ere able to biotinylate p21, confirming the presence of
21 on the outer membrane. Other structural proteins of
MV were analyzed in the biotinylation experiments to
heck that the particles were intact. Almost all of the
urface protein p14 was biotinylated (97%), while only a
uarter of the internal core protein p62 was biotinylated.
he relatively high level of biotinylated p62, considering
149A17L GENE PRODUCT OF VACCINIA VIRUSthat it is a core protein and was not expected to be
labeled, suggests that the particles, to some degree,
were disrupted. The results from the biotinylation studies
are still indicative of the position of proteins in the par-
ticles, since there is a clear gradient of degree of bio-
tinylation corresponding to the different localizations of
the proteins in the particles.
Our results showed that only approximately half of the
p21 was biotinylated, which suggests the presence of
two equivalent pools of p21. Another explanation could
be that p21 was incompletely biotinylated due to poor
accessibility, indicating that p21 might very well exist in a
single pool on the surface of IMV. However, since previ-
ous results have determined the localization of p21 on
the inner membrane of IV (Krijnse-Locker et al., 1996), our
results should be interpreted as p21 being more or less
evenly distributed on both the inner and the outer mem-
branes of IMV. After treatment of purified IMV with tryp-
sin, we found that while the C-terminal part of the mature
p21 was protease resistant, the N-terminal part was
digested, which suggests that this domain is exposed on
the surface of IMV. Purified virions used in the experi-
ments were shown to be intact by determining protease
sensitivity of other VV proteins. The surface protein p14
(A27L) was completely digested, while the more internal
proteins p15 (A14L) and p65 (D13L) were protease resis-
tant. P8 (A13L) was sensitive, but it was not always
digested, indicating the presence of a bipolar fraction. P8
is a membrane protein believed to localize to both the
inner and the outer membranes of IMV (Salmons et al.,
1997), which is supported by our results.
p21 is thought to span the membrane four times,
adopting a topology in which it exposes both termini on
the cytosolic side of the membrane (Krijnse-Locker et al.,
1996). In accordance with this model, the N-terminus is
exposed on the surface of IMV and hence is accessible
for protease digestion. Protection of the C-terminus of
p21 from protease digestion could be explained if this
domain was embedded in the membrane or in close
contact with it or simply does not protrude on the surface
of the particle. Another possibility could be that a pro-
tease-resistant protein masks it. This masking could not
occur through the interaction with p14, since p14 was
completely digested in the protease assay. Our results
demonstrating that the N-terminal end of p21 was com-
pletely digested when increased amounts of trypsin
were used indicate that the protease would gain access
to the interior of the particle at high concentrations,
which was also demonstrated by the difficulty in achiev-
ing consistent results for internal proteins, since they
were more or less protease resistant in different exper-
iments. Since we did not find a protease-resistant sub-
population of the N-terminus of p21, our results indicate
that p21 exposes its N-terminus in both the outer and the
inner membranes. Thus, p21 would adopt the same, but
inverse, topology in both membranes. According to thefour-transmembrane topology, the two transmembrane
linking sequences (aa 78–81 and aa 139–141) would be
protected in between the tightly apposed membranes,
corresponding to the lumen of ERGIC. The region (aa
99–117) separating the second and the third hydrophobic
stretches would thus form a linking loop located on the
cytosolic side. This region possesses an arginine (aa
108), which is susceptible to cleavage by trypsin, but
nevertheless it was not affected by protease digestion in
our experiments. In the two-transmembrane model of
p21, this arginine-containing region would be protected
from protease digestion in between the two membranes.
Thus, our results support the latter model (Betakova and
Moss, 2000).
All of the above results taken together strongly sug-
gest that p21 is located on the outer membrane of IMV,
as well. Further support was provided by results ob-
tained with antibodies directed to the N-terminus of p21
as well as antibodies directed to the entire p21, which
were capable of neutralizing VV infection. The neutraliz-
ing activity of these p21 antibodies was as strong as that
of the antibody directed to p14. Antibodies to the C-
terminal part of p21 had no effect on virus infection.
Previous studies of p21 localization were done when
the proteolytic cleavage of the protein was not well
characterized. VV-infected cells were studied in immu-
noelectron microscopy using antibodies that were di-
rected to both the N- and the C-terminal regions of the
23-kDa precursor, which we now know are not present in
the processed protein of the IMV. In these experiments,
preferentially the inner, concave membrane of assem-
bling viral crescents and IV were immunolabeled, which
led to the conclusion that p21 was located mainly on the
inner membrane (Krijnse-Locker et al., 1996; Wolffe et al.,
1996). These results could indicate that proteolytic pro-
cessing of the 23-kDa precursor is initiated on the exte-
rior of IV. This would be in agreement with the result
showing that processing was not completed until after
120 min postsynthesis.
p21 is essential for membrane morphogenesis and in
its absence the membranes derived from ERGIC do not
form the rigid crescents that line up around the viral
factories (Rodrı´guez et al., 1995; Wolfe et al., 1996). This
indicates that p21 is involved in shaping the membranes
as well as being responsible for anchoring p14 to the
IMV surface. The possibility also exists that interaction of
p21, localized in the external IMV membrane, with its
counterpart, or the A14L protein, located in the inner
membrane, may contribute to bringing these adjacent
membranes together.
In conclusion, the A17L gene product is synthesized
as a 23-kDa precursor, which is processed in both the N-
and the C-termini to produce the final 21-kDa form, which
is present in IMV particles. Using protease sensitivity,
surface labeling assays, and neutralization of virus infec-
tion, we have shown that p21 is located on the surface of
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150 WALLENGREN ET AL.IMV exposing its N-terminus on the exterior of the mem-
brane. Hence, our results and previous results taken
together suggest that p21 exists in two pools and is thus
located on both the outer and the inner membranes of
IMV.
MATERIALS AND METHODS
Cells and virus
African green monkey kidney cells (BSC-40) were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% newborn calf serum (NCS). The
VV WR strain was propagated and titrated in BSC-40
cells as previously described (Joklik, 1962). IMV particles
were purified by banding on a sucrose gradient (Joklik,
1962).
Antisera
Several antibodies directed against different regions
of the A17L gene product were raised in rabbits by
immunization with synthetic peptides. The following poly-
clonal antibodies were used: aA17L N9, which recog-
izes aa 17–37; aA17L C9 recognizes aa 165–185; aA17L
recognizes aa 193–203 (Rodrı´guez et al., 1996); and
ap21E is raised to the entire p21 (referred to as anti-21-
kDa polyclonal antibody in Va´zquez et al. (1998)). The
regions of the protein recognized by the different anti-
bodies are represented in Fig. 1A. Other antibodies to VV
proteins were ap14 (A27L), ap39 (A5L), ap62 (A10L), ap8
(A13L), ap15 (A14L), ap65 (D13L), and ap32 (D8L). An
unrelated antibody directed to HIV agp120 was used as
a control in the neutralization experiments.
Pulse–chase analysis and immunoprecipitation
BSC-40 cells were infected with VV at 5 PFU per cell.
At 5.5 hpi cells were washed and incubated in methi-
onine-free DMEM for 30 min. Cells were then pulse-
labeled for 5 min with 100 mCi/ml [35S]methionine
Amersham) in the same medium and chased with a
00-fold excess of unlabeled methionine for the indi-
ated times. Cells were lysed in lysis buffer A (1% Non-
det-P40 (NP-40), 80 mM NaCl, 20 mM Tris–HCl (pH 8.0),
0 mM EDTA) and nuclei were removed by 5 min of
entrifugation at 13,000 rpm in an eppendorf centrifuge.
roteins were immunoprecipitated from the lysate for 1 h
t room temperature (RT) or overnight at 4°C, using
ndicated antibodies and 50 ml of 50% protein A–Sepha-
ose beads (Pharmacia) in 10 mM Tris–HCl (pH 7.5)
ontaining 1% nonfat dry milk. The immunoprecipitates
ere washed three times with lysis buffer A and three
imes with PBS and resuspended in 23 sample buffer
1.25 M Tris–HCl, pH 6.8, 4% SDS, 0.25% bromophenol
lue, and 10% 2-mercaptoethanol). Samples were boiled
nd proteins were resolved by SDS–PAGE and visualized
fter fluorography. clectron microscopy
Purified IMV particles from the WR strain of VV were
dsorbed to the surface of EM grids and subjected to
mmunogold labeling. The IMV particles were incubated
ith different antibodies against the A17L gene product
nd against other VV envelope and core proteins and
ubsequently reacted with secondary antibodies conju-
ated with 10-nm colloidal gold particles (Risco et al.,
996; Rodrı´guez et al., 1997). Negative staining with 2%
ranyl acetate was performed as previously described
Rodrı´guez et al., 1996). Immunogold labeling on thin
ections of VV-infected Hela cells was performed as
escribed (Rodriguez et al., 1997). Samples were studied
n a Jeol 1200EX II electron microscope.
iotinylation of purified virions
Purified virions were treated with 1 mg/ml NHS-SS-
iotin (Pierce) for 30 min on ice. The biotinylation reac-
ion was stopped by adding NH4Cl to a concentration of
50 mM. Virus particles were subjected to centrifugation
for 30 min at 13,000 rpm in an eppendorf centrifuge at
4°C and washed with 50 mM NH4Cl. After a second
centrifugation they were washed with 1 mM NH4Cl and
resubjected to centrifugation. The resulting pellet was
resuspended in lysis buffer B (1% NP-40, 150 mM NaCl,
50 mM Tris–HCl (pH 7.6), 2 mM EDTA), incubated for 30
min at 37°C, and sonicated twice for 10 s. The lysate was
subjected to centrifugation for 5 min at 13,000 rpm in an
eppendorf centrifuge and the resulting pellet was resus-
pended in lysis buffer and treated as above. The two
supernatants were pooled and incubated with 50%
streptavidin–agarose (Sigma) for 1 h at RT or overnight at
4°C. The sample was subjected to centrifugation for 1
min at 13,000 rpm in an eppendorf centrifuge. The su-
pernatant was recovered and mixed (vol:vol) with 23
sample buffer to analyze the material that had not bound
to the streptavidin. The streptavidin–agarose pellet con-
taining the bound proteins was washed once with buffer
1 (50 mM Tris–HCl (pH 8.0), 100 mM NaCl, 1% TX-100,
0.1% SDS, 0.2% bovine serum albumin (BSA), 0.2 mM
phenylmethylsulfonyl fluoride (PMSF)), three times with
buffer 2 (200 mM Tris–HCl (pH 8.0), 150 mM NaCl, 0.5%
TX-100, 0.1% SDS, 0.2% BSA, 0.2 mM PMSF), three times
ith buffer 3 (50 mM Tris–HCl (pH 8.0), 1 M NaCl, 1%
X-100, 0.1% SDS, 0.2% BSA, 0.2 mM PMSF), and twice
ith buffer 4 (10 mM Tris–HCl (pH 8.0)) by subjecting the
ample to centrifugation for 1 min at 13,000 rpm in an
ppendorf centrifuge between each wash. Sample buffer
as added to the streptavidin–agarose and boiled for 5
in. Samples were analyzed by SDS–PAGE and Western
lot.
rotease digestion of purified virionsPurified virions were treated with trypsin at various
oncentrations (0.2, 2, 20, and 200 mg/ml) for 30 min at
RS
151A17L GENE PRODUCT OF VACCINIA VIRUS37°C. The trypsin reaction was stopped by adding apro-
tinin and PMSF to a concentration of 4 and 100 mg/ml,
respectively. Then 23 sample buffer was added and
samples were boiled immediately for 5 min. Samples
were analyzed by 12% SDS–PAGE and transferred to
nitrocellulose membranes. The membranes were incu-
bated with specific antibodies and immunoreactive
bands were detected by chemiluminescence using ECL
(Amersham Pharmacia Biotech).
Neutralization of VV infection
Aliquots of VV containing 100 PFU were incubated with
different dilutions (1:100, 1:500) of indicated antibodies in
DMEM for 30 min at 37°C before being added to conflu-
ent monolayers of BSC-40 cells. After 1 h of virus adsorp-
tion, the inoculum was removed and cells were overlaid
with 0.9% agarose in DMEM supplemented with 2% NCS.
At 48 hpi, the solid medium was removed and the cells
were stained with 1% crystal violet in 2% methanol.
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